SI1177190T1 - Uporaba dolocenih antagonistov alfa 1-b andrenergicnega receptorja za zdravljenje spolne disfunkcije - Google Patents
Uporaba dolocenih antagonistov alfa 1-b andrenergicnega receptorja za zdravljenje spolne disfunkcijeInfo
- Publication number
- SI1177190T1 SI1177190T1 SI200030764T SI200030764T SI1177190T1 SI 1177190 T1 SI1177190 T1 SI 1177190T1 SI 200030764 T SI200030764 T SI 200030764T SI 200030764 T SI200030764 T SI 200030764T SI 1177190 T1 SI1177190 T1 SI 1177190T1
- Authority
- SI
- Slovenia
- Prior art keywords
- alpha
- adrenergic receptor
- sexual dysfunction
- selective antagonists
- improvement
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
- G01N33/9433—(Nor)adrenaline
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Reproductive Health (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Electrotherapy Devices (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT1999MI000995A IT1312310B1 (it) | 1999-05-07 | 1999-05-07 | Uso di antagonisti selettivi del recettore adrenergico a 1b per ilmiglioramento della disfunzione sessuale |
| PCT/EP2000/004308 WO2000067735A2 (en) | 1999-05-07 | 2000-05-08 | USE OF SELECTIVE ANTAGONISTS OF THE α1b-ADRENERGIC RECEPTOR FOR IMPROVEMENT OF SEXUAL DYSFUNCTION |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI1177190T1 true SI1177190T1 (sl) | 2006-02-28 |
Family
ID=11382912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200030764T SI1177190T1 (sl) | 1999-05-07 | 2000-05-08 | Uporaba dolocenih antagonistov alfa 1-b andrenergicnega receptorja za zdravljenje spolne disfunkcije |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US6303606B1 (sl) |
| EP (1) | EP1177190B1 (sl) |
| JP (1) | JP2002544158A (sl) |
| KR (1) | KR100696755B1 (sl) |
| CN (1) | CN1150187C (sl) |
| AT (1) | ATE308538T1 (sl) |
| AU (1) | AU765487B2 (sl) |
| BR (1) | BR0010348A (sl) |
| CA (1) | CA2366201A1 (sl) |
| DE (1) | DE60023686T2 (sl) |
| DK (1) | DK1177190T3 (sl) |
| ES (1) | ES2250130T3 (sl) |
| HK (1) | HK1039900B (sl) |
| HU (1) | HUP0201184A3 (sl) |
| IL (1) | IL146003A0 (sl) |
| IT (1) | IT1312310B1 (sl) |
| MX (1) | MXPA01011261A (sl) |
| NO (1) | NO321841B1 (sl) |
| NZ (1) | NZ515240A (sl) |
| PL (1) | PL196708B1 (sl) |
| RU (1) | RU2239633C2 (sl) |
| SI (1) | SI1177190T1 (sl) |
| TW (1) | TWI224503B (sl) |
| WO (1) | WO2000067735A2 (sl) |
| ZA (1) | ZA200110042B (sl) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040014761A1 (en) * | 1997-10-28 | 2004-01-22 | Place Virgil A. | Treatment of female sexual dysfunction with phosphodiesterase inhibitors |
| GB0000561D0 (en) * | 2000-01-11 | 2000-03-01 | Pfizer Ltd | Treatment of diabetic ulcers |
| US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
| UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| GB0222522D0 (en) | 2002-09-27 | 2002-11-06 | Controlled Therapeutics Sct | Water-swellable polymers |
| GB0225908D0 (en) * | 2002-11-06 | 2002-12-11 | Pfizer Ltd | Treatment of female sexual dysfunction |
| WO2005025570A1 (en) * | 2003-09-15 | 2005-03-24 | Diamedica Inc. | Use of antagonists of hepatic sympathetic nerve activity |
| US20050124625A1 (en) * | 2003-10-21 | 2005-06-09 | Salvati Mark E. | Piperazine derivatives and their use as modulators of nuclear hormone receptor function |
| WO2005112889A2 (en) * | 2004-05-20 | 2005-12-01 | Recordati Ireland Limited | Transmucosal delivery formulations |
| GB0417401D0 (en) | 2004-08-05 | 2004-09-08 | Controlled Therapeutics Sct | Stabilised prostaglandin composition |
| WO2006042701A1 (de) * | 2004-10-18 | 2006-04-27 | Polymun Scientific Immunbiologische Forschung Gmbh | Liposomale zusammensetzung einen wirkstoff zur relaxierung glatter muskulatur enthaltend, die herstellung dieser zusammensetzung und deren therapeutische verwendung |
| US8227476B2 (en) | 2005-08-03 | 2012-07-24 | Sprout Pharmaceuticals, Inc. | Use of flibanserin in the treatment of obesity |
| US7923449B2 (en) | 2005-10-29 | 2011-04-12 | Boehringer Ingelheim International Gmbh | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
| ES2336719T3 (es) | 2006-06-30 | 2010-04-15 | Boehringer Ingelheim International Gmbh | Flibanserina para el tratamiento de la incontinencia urinaria y las enfermedades relacionadas. |
| GB0613333D0 (en) | 2006-07-05 | 2006-08-16 | Controlled Therapeutics Sct | Hydrophilic polyurethane compositions |
| GB0613638D0 (en) | 2006-07-08 | 2006-08-16 | Controlled Therapeutics Sct | Polyurethane elastomers |
| CA2660476C (en) | 2006-08-14 | 2015-11-17 | Boehringer Ingelheim International Gmbh | Formulations of flibanserin and method for manufacturing the same |
| CA2661613C (en) | 2006-08-25 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Controlled release system and method for manufacturing the same |
| GB0620685D0 (en) | 2006-10-18 | 2006-11-29 | Controlled Therapeutics Sct | Bioresorbable polymers |
| UY31335A1 (es) | 2007-09-12 | 2009-04-30 | Tratamiento de sintomas vasomotores | |
| CN101592613B (zh) * | 2009-07-06 | 2011-12-21 | 广东省药品检验所 | 一种中成药、保健食品和食品中添加pde5型抑制剂的检测方法 |
| BR112013005823B8 (pt) * | 2010-09-13 | 2022-11-22 | Otsuka Pharma Co Ltd | Compostos heterocíclicos para o tratamento ou prevenção de distúrbios causados pela neurotransmissão reduzida de serotonina, norefnefrina ou dopamina |
| JP6415982B2 (ja) * | 2012-03-12 | 2018-10-31 | 大塚製薬株式会社 | 複素環化合物 |
| US20130315891A1 (en) | 2012-05-25 | 2013-11-28 | Matthew Charles | Formulations of human tissue kallikrein-1 for parenteral delivery and related methods |
| SI2854841T1 (sl) | 2012-06-04 | 2017-06-30 | Diamedica Inc. | Glikozilacijske izooblike humanega tkivnega kalikreina-1 |
| WO2017168174A1 (en) | 2016-04-02 | 2017-10-05 | N4 Pharma Uk Limited | New pharmaceutical forms of sildenafil |
| RU2018145364A (ru) | 2016-06-27 | 2020-07-28 | Ачиллион Фармасьютикалс, Инк. | Хиназолиновые и индольные соединения для лечения медицинских нарушений |
| US11857608B2 (en) | 2017-03-09 | 2024-01-02 | Diamedica Inc. | Dosage forms of tissue kallikrein 1 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5605897A (en) | 1991-04-23 | 1997-02-25 | Eli Lilly And Company | 2-methyl-thieno-benzodiazepine |
| IT1254469B (it) | 1992-02-25 | 1995-09-25 | Recordati Chem Pharm | Derivati benzopiranici e benzotiopiranici |
| US5474994A (en) | 1992-05-26 | 1995-12-12 | Recordati S.A., Chemical And Pharmaceutical Company | Bicyclic heterocyclic derivatives having α1 -adrenergic and 5HT1A |
| US5773457A (en) | 1995-02-15 | 1998-06-30 | Cesar Roberto Dias Nahoum | Compositions |
| EP0611248B1 (en) | 1993-02-10 | 2000-03-22 | B.M.R.A. Corporation B.V. | Pharmaceutical composition for treating impotence containing an alpha-1-inhibitor and an alpha-2 inhibitor |
| US5565466A (en) | 1993-08-13 | 1996-10-15 | Zonagen, Inc. | Methods for modulating the human sexual response |
| IT1270993B (it) * | 1994-03-18 | 1997-05-26 | Recordati Chem Pharm | Derivati chinzolilamminici attivi come alfa-antagonisti |
| TR199700930T2 (xx) | 1995-03-14 | 1998-07-21 | Vivus Incorporated | Ereksiyon bozuklu�unu �nlemek i�in y�ntem ve kit. |
| US5731339A (en) | 1995-04-28 | 1998-03-24 | Zonagen, Inc. | Methods and formulations for modulating the human sexual response |
| EP0853479A4 (en) | 1995-09-29 | 2001-04-11 | Merck & Co Inc | ALPHA 1b ADRENERGIC RECEPTOR ANTAGONISTS |
| US5700364A (en) | 1995-10-30 | 1997-12-23 | Merck & Co., Inc. | Electrochemical oxidation |
| US5932538A (en) * | 1996-02-02 | 1999-08-03 | Nitromed, Inc. | Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses |
| US5877216A (en) | 1997-10-28 | 1999-03-02 | Vivus, Incorporated | Treatment of female sexual dysfunction |
| CA2305394C (en) * | 1997-10-28 | 2006-12-12 | Vivus, Incorporated | Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| WO1999021562A1 (en) | 1997-10-28 | 1999-05-06 | Asivi, Llc | Treatment of female sexual dysfunction |
-
1999
- 1999-05-07 IT IT1999MI000995A patent/IT1312310B1/it active
-
2000
- 2000-04-27 TW TW089108045A patent/TWI224503B/zh not_active IP Right Cessation
- 2000-05-05 US US09/565,842 patent/US6303606B1/en not_active Expired - Fee Related
- 2000-05-08 RU RU2001133004/04A patent/RU2239633C2/ru not_active IP Right Cessation
- 2000-05-08 DK DK00927199T patent/DK1177190T3/da active
- 2000-05-08 ES ES00927199T patent/ES2250130T3/es not_active Expired - Lifetime
- 2000-05-08 CA CA002366201A patent/CA2366201A1/en not_active Abandoned
- 2000-05-08 IL IL14600300A patent/IL146003A0/xx unknown
- 2000-05-08 WO PCT/EP2000/004308 patent/WO2000067735A2/en active IP Right Grant
- 2000-05-08 JP JP2000616762A patent/JP2002544158A/ja active Pending
- 2000-05-08 AU AU45654/00A patent/AU765487B2/en not_active Ceased
- 2000-05-08 KR KR1020017014073A patent/KR100696755B1/ko not_active IP Right Cessation
- 2000-05-08 SI SI200030764T patent/SI1177190T1/sl unknown
- 2000-05-08 BR BR0010348-9A patent/BR0010348A/pt not_active Application Discontinuation
- 2000-05-08 CN CNB008071764A patent/CN1150187C/zh not_active Expired - Fee Related
- 2000-05-08 AT AT00927199T patent/ATE308538T1/de not_active IP Right Cessation
- 2000-05-08 EP EP00927199A patent/EP1177190B1/en not_active Expired - Lifetime
- 2000-05-08 MX MXPA01011261A patent/MXPA01011261A/es active IP Right Grant
- 2000-05-08 HU HU0201184A patent/HUP0201184A3/hu unknown
- 2000-05-08 NZ NZ515240A patent/NZ515240A/en unknown
- 2000-05-08 PL PL351624A patent/PL196708B1/pl unknown
- 2000-05-08 DE DE60023686T patent/DE60023686T2/de not_active Expired - Fee Related
-
2001
- 2001-08-22 US US09/935,288 patent/US6953800B2/en not_active Expired - Fee Related
- 2001-11-06 NO NO20015428A patent/NO321841B1/no unknown
- 2001-12-06 ZA ZA200110042A patent/ZA200110042B/xx unknown
-
2002
- 2002-02-26 HK HK02101448.4A patent/HK1039900B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1039900A1 (en) | Use of selective antagonists of the alpha1b-adrenergic receptor for improvement of sexual dysfunction | |
| EP1027011A4 (en) | ADMINISTRATION OF 5-HT RECEPTOR AGONISTS AND ANTAGONISTS INCLUDING ACTIVE SUBSTANCES FOR THE TREATMENT OF EARLY SEED EATING | |
| HUP0204159A3 (en) | Prostaglandin compositions and their use for preparation of pharmaceutical compositions for treatment male erectile dysfunction | |
| HK1036970A1 (en) | Compounds and compositions for delivering active agents. | |
| IL172833A0 (en) | Pyrimidine-2,4-dione derivatives and pharmaceutical compositions containing the same | |
| YU20600A (sh) | Nova upotreba antagonista 5-ht3 receptora | |
| AU1192302A (en) | Inhibition of emetic effect of metformin with 5-ht3 receptor antagonists | |
| PT1299348E (pt) | Compostos e composições para administração de agentes activos | |
| UA41316C2 (uk) | Трициклічні похідні піролу і фармацевтичний препарат | |
| PA8504501A1 (es) | Compuestos farmaceuticamente activos | |
| SG188700A1 (en) | Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors | |
| HUP0001089A2 (hu) | Gyógyászati készítmények férfiak erekciós zavarainak kezelésére | |
| HUP0301892A2 (hu) | Szexuális zavarok kezelésére szolgáló gyógyszerkészítmények és előállításuk | |
| BR9911408A (pt) | Formas de dosagem contendo apomorfina paramelhora de disfunção erétil masculina | |
| MY133423A (en) | Pharmaceutical combinations and their use in treating gastrointestinal disorders | |
| EP1015008A4 (en) | COMPOUNDS AND COMPOSITIONS FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES | |
| IL172834A0 (en) | Pyrimidine-,2,4-dione derivatives and pharmaceutical compositions containing the same | |
| YU49202A (sh) | Benzazolski derivati i njihova upotreba kao modulatora jnk | |
| AU2001285318A1 (en) | Use of an aldosterone receptor antagonist to improve cognitive function | |
| ZA200007019B (en) | Use of prostaglandin agonists to treat erectile dysfunction or impotence. | |
| BG106602A (en) | Formulation of substituted benzimidazoles | |
| DK1109814T3 (da) | 5-Heterocyclylpyrazolo[4,3-d]pyrimidin-7-oner til behandling af mandlig erektil dysfunktion | |
| NZ512137A (en) | Prostaglandin E2 (PGE2) and PGE4 analogues, which are antagonists of the EP2 receptor for treatment of female sexual dysfunction | |
| MXPA03004547A (es) | Agonistas receptores de d4 de dopamina selectivos para el tratamiento de disfuncion sexual. | |
| AU2003226765A8 (en) | Azaindolylpiperidine derivatives as antihistaminic and antiallergic agents |